Skip to content
Sign in

LAB · NASDAQ

Standard BioTools (LAB) Stock Price & Fundamentals

$583.57+0.38%+$2.23End-of-day price as of Oct 9, 2026

Standard BioTools (LAB) closed at $583.57 on Oct 9, 2026, up 0.38% from the previous close of $581.34.

Share price, past year

1Y +23.52%

52-week range $471.17 – $583.57. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$583.57
Sep 30, 2026$569.04
Aug 31, 2026$523.14
Jul 31, 2026$517.12
Jun 30, 2026$562.68
May 29, 2026$541.86
Apr 30, 2026$525.91
Mar 31, 2026$517.41
Feb 27, 2026$505.67
Jan 30, 2026$523.63
Dec 31, 2025$522.95
Nov 28, 2025$499.73
Oct 31, 2025$476.26

Key statistics

Market cap
$228.83B
P/E (TTM)
2,652.6
EPS (TTM)
$0.22
Revenue (TTM)
$84.60M
Net income (TTM)
$84.91M
Shares outstanding
392.1M
Dividend yield
—
52-week range
$471.17 – $583.57

Standard BioTools's market cap is $228.83B, based on a share price of $583.57 and 392.1M shares outstanding as of Jun 30, 2026.

Financials

Standard BioTools reported revenue of $85.33M for fiscal 2025, down 6.24% from fiscal 2024.

Standard BioTools reported a net loss of $74.90M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Standard BioTools annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$85.33M−6.2%−$74.90M−87.8%−$0.20−$82.65M
FY2024ended Dec 31, 2024$91.01M−14.4%−$138.89M−152.6%−$0.52−$151.81M
FY2023ended Dec 31, 2023$106.34M+8.6%−$74.66M−70.2%−$0.94−$46.12M
FY2022ended Dec 31, 2022$97.95M−25.0%−$190.10M−194.1%−$2.43−$93.20M
FY2021ended Dec 31, 2021$130.58M−5.5%−$59.24M−45.4%−$0.78−$57.33M
FY2020ended Dec 31, 2020$138.14M+17.8%−$53.02M−38.4%−$0.74−$28.13M
FY2019ended Dec 31, 2019$117.24M+3.8%−$64.79M−55.3%−$0.97−$37.74M
FY2018ended Dec 31, 2018$112.96M+10.8%−$59.01M−52.2%−$1.49−$25.57M
FY2017ended Dec 31, 2017$101.94M−2.4%−$60.54M−59.4%−$1.84−$25.66M
FY2016ended Dec 31, 2016$104.45M—−$75.99M−72.8%−$2.62−$44.20M
Standard BioTools quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$20.10M−$26.76M−$0.07
Q1 FY2026ended Mar 31, 2026$21.15M$127.07M$0.33
Q4 FY2025ended Dec 31, 2025$23.80M$19.28M$0.05
Q3 FY2025ended Sep 30, 2025$19.55M−$34.69M−$0.09
Q2 FY2025ended Jun 30, 2025$21.76M−$33.46M−$0.09
Q1 FY2025ended Mar 31, 2025$20.22M−$26.03M−$0.07
Q4 FY2024ended Dec 31, 2024$890.00K−$34.07M−$0.06
Q3 FY2024ended Sep 30, 2024$22.09M−$26.94M−$0.07

Company profile

Name
Standard BioTools Inc.
Ticker
LAB
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
50 Milk Street, 10th Floor, Boston, MA 02109
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001162194

Recent SEC filings

Frequently asked questions

What is Standard BioTools's stock price?

Standard BioTools (LAB) closed at $583.57 on Oct 9, 2026, up 0.38% from the previous close of $581.34.

What is Standard BioTools's market cap?

Standard BioTools's market cap is $228.83B, based on a share price of $583.57 and 392.1M shares outstanding as of Jun 30, 2026.

How much revenue does Standard BioTools make?

Standard BioTools reported revenue of $85.33M for fiscal 2025, down 6.24% from fiscal 2024.

What is LAB's P/E ratio?

Standard BioTools's price-to-earnings ratio is 2,652.6, based on trailing twelve-month diluted EPS of $0.22.

Does Standard BioTools pay a dividend?

Standard BioTools's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Standard BioTools Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures